Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1998 Jul;42(7):1853-7.
doi: 10.1128/AAC.42.7.1853.

Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis

Affiliations

Contribution of rpoB mutations to development of rifamycin cross-resistance in Mycobacterium tuberculosis

D L Williams et al. Antimicrob Agents Chemother. 1998 Jul.

Abstract

The contributions of 23 insertion, deletion, or missense mutations within an 81-bp fragment of rpoB, the gene encoding the beta-subunit of the DNA-dependent RNA polymerase of Mycobacterium tuberculosis, to the development of resistance to rifamycins (rifampin, rifabutin, rifapentine, and KRM-1648) in 29 rifampin-resistant clinical isolates were defined. Specific mutant rpoB alleles led to the development of cross-resistance to all rifamycins tested, while a subset of mutations were associated with resistance to rifampin and rifapentine but not to KRM-1648 or rifabutin. To further study the impact of specific rpoB mutant alleles on the development of rifamycin resistance, mutations were incorporated into the rpoB gene of M. tuberculosis H37Rv, contained on a mycobacterial shuttle plasmid, by in vitro mutagenesis. Recombinant M. tuberculosis clones containing plasmids with specific mutations in either codon 531 or 526 of rpoB exhibited high-level resistance to all rifamycins tested, whereas clones containing a plasmid with a mutation in codon 516 exhibited high-level resistance to rifampin and rifapentine but were susceptible to both rifabutin and KRM-1648. These results provided additional proof of the association of specific rpoB mutations with the development of rifamycin resistance and corroborate previous reports of the usefulness of rpoB genotyping for predicting rifamycin-resistant phenotypes.

PubMed Disclaimer

Figures

FIG. 1
FIG. 1
Nucleotide substitutions were incorporated into the rpoB gene of M. tuberculosis H37Rv contained on pLN-2, using mutagenic primers (Table 3) and long-fragment PCR–site-directed mutagenesis. (A) Signature nucleotides were incorporated into pLN-2 at codons 510 (CAG→CAA) and 511 (CTG→CTA) to yield the pLN-sig plasmid. (B) Mutant rpoB alleles were incorporated into pLN-sig as follows: 1) a GAC→GTC nucleotide substitution in codon 516 of pLN-sig to yield plasmid pAV, 2) a CAC→TAC nucleotide substitution in codon 526 of pLN-sig to yield plasmid pHT, and 3) a TCG→TTG nucleotide substitution in codon 531 of pLN-sig to yield plasmid pSL.

References

    1. Bodmer T, Zurcher G, Imboden P, Telenti A. Mutation position and type of substitution in the β-subunit of the RNA polymerase influence in-vitro activity of rifamycins in rifampicin-resistant Mycobacterium tuberculosis. J Antimicrob Chemother. 1995;35:345–348. - PubMed
    1. De Beenhouwer H, Lhiang Z, Jannes G, Mijs W, Machtelinckx L, Rossau R, Traore H, Portaels F. Rapid detection of rifampicin resistance in sputum and biopsy specimens from tuberculosis patients by PCR and line probe assay. Tubercle Lung Dis. 1995;76:425–430. - PubMed
    1. Heifets L B, Lindholm-Levy P J, Flory M A. Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis. Am Rev Respir Dis. 1990;141:626–630. - PubMed
    1. Hong Kong Chest Service and British Medical Research Council. A controlled study of rifabutin and an uncontrolled study of ofloxacin in the treatment of patients with pulmonary tuberculosis resistant to isoniazid, streptomycin and rifampicin. Tubercle Lung Dis. 1992;73:59–67. - PubMed
    1. Luna-Herrera J, Reddy M V, Gangadharam P R J. In vitro activity of the benzoxazinorifamycin KRM-1648 against drug-susceptible and multidrug-resistant tubercle bacilli. Antimicrob Agents Chemother. 1995;39:440–444. - PMC - PubMed

Publication types

MeSH terms